TCIM
BOLD

TIAA CREF Investment Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

TIAA CREF Investment Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.64M Buy
93,275
+22,026
+31% +$632K ﹤0.01% 1646
2018
Q4 		$1.52M Buy
71,249
+3,470
+5% +$89.5K ﹤0.01% 2110
2018
Q3 		$2.68M Sell
67,779
-5,314
-7% -$198K ﹤0.01% 1964
2018
Q2 		$2.79M Buy
73,093
+26,123
+56% +$968K ﹤0.01% 1990
2018
Q1 		$1.41M Sell
46,970
-8,501
-15% -$288K ﹤0.01% 2272
2017
Q4 		$1.73M Sell
55,471
-2,636
-5% -$72.4K ﹤0.01% 2213
2017
Q3 		$1.63M Sell
58,107
-6,390
-10% -$139K ﹤0.01% 2282
2017
Q2 		$1.23M Buy
64,497
+52,965
+459% +$846K ﹤0.01% 2447
2017
Q1 		$197K Sell
11,532
-334
-3% -$5.4K ﹤0.01% 2998
2016
Q4 		$217K Buy
+11,866
New +$205K ﹤0.01% 3032

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TIAA CREF Investment Management's BOLD Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Audentes Therapeutics, Inc (BOLD) stake by 31% in Q1 2019, buying an estimated $632K and bringing the position to 93,275 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1646.

TIAA CREF Investment Management first reported a position in BOLD in Q4 2016 and has held it in 10 quarters since. 139 funds tracked by Wall St. Rank hold BOLD as of Q1 2019.

  • TIAA CREF Investment Management held 93,275 shares of Audentes Therapeutics, Inc worth $3.64M as of Q1 2019.
  • TIAA CREF Investment Management bought 22,026 Audentes Therapeutics, Inc shares in Q1 2019, an estimated $632K.
  • Audentes Therapeutics, Inc made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1646 holding.
  • TIAA CREF Investment Management first reported a position in Audentes Therapeutics, Inc in Q4 2016 and has held it in 10 quarters since.
  • 139 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.